Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Vaccine Watch
  • Published:

Malaria vaccines: the stage we are at

Nature Reviews Microbiology volume 5, pages 487–489 (2007)Cite this article

A Corrigendum to this article was published on 08 March 2011

This article has been updated

Abstract

With over 1 million deaths annually attributed to malaria, an effective vaccine is an urgently needed intervention. However, the various stages of the malaria parasite lifecycle have differing protective immune mechanisms and clinical endpoints, and usually different, often polymorphic, antigens. Trials using an increasing variety of vaccine platforms and antigens are under way in an attempt to achieve this long-awaited goal.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Global distribution of malaria incidence.

Change history

  • 08 March 2011

    The authors wish to acknowledge that they were supported by funding from the UK National Institute for Health Research (NIHR) Oxford Biomedical Research Centre programme at the time of writing. The authors apologize for the oversight.

References

  1. Hay, S. I. & Snow, R. W. The malaria atlas project: developing global maps of malaria risk. PLoS Med. 3, e473 (2006).

    Article  PubMed  PubMed Central  Google Scholar 

  2. WHO. World Malaria Report. [online] (2005).

  3. Hill, A. V. Pre-erythrocytic malaria vaccines: towards greater efficacy. Nature Rev. Immunol. 6, 21–32 (2006).

    Article  CAS  Google Scholar 

  4. Alonso, P. L. et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364, 1411–1420 (2004).

    Article  CAS  PubMed  Google Scholar 

  5. Alonso, P. L. et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366, 2012–2018 (2005).

    Article  CAS  PubMed  Google Scholar 

  6. Webster, D. P. et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl Acad. Sci. USA 102, 4836–4841 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Keating, S. M. et al. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J. Immunol. 175, 5675–5680 (2005).

    Article  CAS  PubMed  Google Scholar 

  8. Bejon, P. et al. A Phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin. Trials 1, e29 (2006).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Prieur, E. et al. A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. Proc. Natl Acad. Sci. USA 101, 290–295 (2004).

    Article  CAS  PubMed  Google Scholar 

  10. Li, S. et al. Viral vectors for malaria vaccine development. Vaccine 25, 2567–2574 (2007).

    Article  CAS  PubMed  Google Scholar 

  11. Stewart, V. A. et al. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect. Immun. 75, 2283–2290 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Genton, B. et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine 22, 30–41 (2003).

    Article  CAS  PubMed  Google Scholar 

  13. Thera, M. A. et al. Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a Phase I randomized trial. PLoS Clin. Trials 1, e34 (2006).

    Article  PubMed  PubMed Central  Google Scholar 

  14. Sirima, S. B. et al. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine 25, 2723–2732 (2007).

    Article  CAS  PubMed  Google Scholar 

  15. Brando, C. et al. Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A. Infect. Immun. 75, 838–845 (2007).

    Article  CAS  PubMed  Google Scholar 

  16. Stoute, J. A. et al. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine 25, 176–184 (2007).

    Article  CAS  PubMed  Google Scholar 

  17. Polhemus, M. E. et al. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 25, 4203–4212 (2007).

    Article  CAS  PubMed  Google Scholar 

  18. Malkin, E. et al. Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria. PLoS Clin. Trials 2, e12 (2007).

    Article  PubMed  PubMed Central  Google Scholar 

  19. Theisen, M. et al. Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies. Vaccine 22, 1188–1198 (2004).

    Article  CAS  PubMed  Google Scholar 

  20. Langermans, J. A. et al. Preclinical evaluation of a chimeric malaria vaccine candidate in Montanide ISA 720: immunogenicity and safety in rhesus macaques. Hum. Vaccin. 2, 222–226 (2006).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank the UK National Institute for Health Research Oxford Biomedical Research Centre programme for funding.

Author information

Authors and Affiliations

  1. Stephen M. Todryk is at the Cente for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, UK.,

    Stephen M. Todryk

  2. Nuffield Department of Medicine, Adrian V. S. Hill is at the Centre for Clinical Vaccinology and Tropical Medicine and Wellcome Trust Centre for Human Genetics, University of Oxford, Churchill Hospital, Oxford, UK.,

    Adrian V. S. Hill

Authors
  1. Stephen M. Todryk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adrian V. S. Hill
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen M. Todryk.

Related links

Related links

DATABASES

Entrez Genome Project

Plasmodium falciparum

Rights and permissions

Reprints and permissions

About this article

Cite this article

Todryk, S., Hill, A. Malaria vaccines: the stage we are at. Nat Rev Microbiol 5, 487–489 (2007). https://doi.org/10.1038/nrmicro1712

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrmicro1712

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing